TheraCryf PLC
TCF
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,052.70 | 80.40 | -0.99% |
| CAC 40 | 7,652.03 | 206.80 | -2.63% |
| DAX 40 | 21,881.47 | 509.37 | -2.27% |
| Dow JONES (US) | 42,225.32 | 235.36 | 0.56% |
| FTSE 100 | 8,482.88 | 125.60 | -1.46% |
| HKSE | 22,849.81 | 352.72 | -1.52% |
| NASDAQ | 17,601.05 | 151.16 | 0.87% |
| Nikkei 225 | 34,735.93 | 989.94 | -2.77% |
| NZX 50 Index | 12,338.57 | 18.38 | 0.15% |
| S&P 500 | 5,670.97 | 37.90 | 0.67% |
| S&P/ASX 200 | 7,859.70 | 74.80 | -0.94% |
| SSE Composite Index | 3,342.01 | 8.12 | -0.24% |